Archive for November, 2011

Discovery IGS 730 Interventional Imaging System from GE

Discovery IGS 730 Interventional Imaging System from GE

A Revolution in Minimally Invasive Imaging: GE Healthcare Unveils New Category of Interventional Imaging Systems

CHICAGO — November 27, 2011 At RSNA 2011, GE Healthcare (NYSE: GE) will reveal the Discovery IGS 730[1], the first Interventional X-ray system designed to capture the advantages of both floor- and ceiling-mounted systems. With laser-guided motion technology on a motorized mobile gantry for predictable and precise trajectories, Wide Bore 3D for ease in 3D acquisitions, and more than 20 advanced applications available, the Discovery IGS 730 is positioned for a new era of interventional procedures. The significance of this innovation to interventional imaging has been compared to that of the invention of flat panel technology.

“Our goal was to pioneer a solution that eliminates the historical trade-offs our customers had to make when selecting from the interventional imaging systems. In general, the trade-off between ceiling- and floor-mounted systems means compromising patient access for room airflow and sterility, while the choice between fixed units and mobile C-arms means compromising image quality for mobility. Now interventionalists and surgeons who perform complex minimally invasive procedures have an entirely new category of imaging system that eliminates the need to compromise: Discovery. At GE Healthcare, we believe the Discovery IGS 730 has the potential to revolutionize the field of interventional imaging,” said Hooman Hakami, president and CEO of GE Healthcare Interventional Systems.

The Discovery IGS 730 is a revolution in imaging. It is neither floor- nor ceiling-mounted, but enables full patient access without the need to suspend the system above the patient. It has the mobility of a C-arm with the power and image quality of a fixed system. This laser-guided, motorized mobile gantry creates an interventional environment without boundaries. It allows complete access to the patient and unlimited parking capability, while creating sterility for a flexible and secure OR environment. The unique gantry comes with a new wide bore design, which allows for steep angles, ease in 3D acquisition, especially for large patients.

The Discovery IGS 730 C-arm is mounted on an Advanced Guided Vehicle (AGV), a motorized and fully mobile system. Based on laser guidance, the AGV can move freely from imaging position to parking or back-out positions, using predefined trajectories to provide total patient access. The Discovery IGS 730 features One-Touch-Back-Out, enabling fast and easy gantry movement away from the patient. The motion is predictable, precise and easy to use, allowing fine control and positioning at any moment in the procedure. Parking locations and back-out distances are customizable for different room configurations.

“My first impression was that this system will allow us to have levels of access to patients in ways we have never had before. This particular unit removes the limitations of both ceiling- and floor-mounted systems without losing any of the advantages,” said Dr. Hal Folander, chairman of the Radiology Department and Section Chief of Interventional Radiology at St. Luke’s Hospital and Health Network in Pennsylvania, who has participated in clinical simulations on phantoms using the Discovery IGS 730. “Having been involved in research and development of this type of product for 25 years, I would say this is, probably, one of the most revolutionary interventional projects that I’ve seen. The innovation will be equivalent to or greater than the invention of flat panel technology for interventional procedures.”

In addition to being mobile, Discovery IGS 730 comes equipped with more than 20 advanced applications. One example is the new Wide Bore 3D application for ease in 3D acquisitions and the ability to allow off-centered 3D acquisitions to cover anatomies such as the borders of the liver during liver oncology procedures or the skin line during image-guided needle procedures.

“With Discovery IGS 730, doctors will be able to rediscover space and movement while accessing all the advanced imaging capabilities of GE premium interventional systems,” said Chantal Le Chat, general manager of GE Healthcare Interventional Radiology.

GE Healthcare at RSNA 2011

Each year in Chicago, the conference of the Radiological Society of North America (RSNA) provides a forum for showcasing the latest innovations in medical imaging. If you are attending the conference, please visit GE Healthcare at booth 3335 in McCormick Place south hall. Throughout the week of the event, GE Healthcare will distribute news and information using these digital platforms:

About GE Healthcare

GE Healthcare provides transformational medical technologies and services that are shaping a new age of patient care. Our broad expertise in medical imaging and information technologies, medical diagnostics, patient monitoring systems, drug discovery, biopharmaceutical manufacturing technologies, performance improvement and performance solutions services help our customers to deliver better care to more people around the world at a lower cost. In addition, we partner with healthcare leaders, striving to leverage the global policy change necessary to implement a successful shift to sustainable healthcare systems.

Our “healthymagination” vision for the future invites the world to join us on our journey as we continuously develop innovations focused on reducing costs, increasing access and improving quality around the world. Headquartered in the United Kingdom, GE Healthcare is a unit of General Electric Company (NYSE: GE). Worldwide, GE Healthcare employees are committed to serving healthcare professionals and their patients in more than 100 countries.  For more information about GE Healthcare, visit our website at www.gehealthcare.com.

For our latest news, please visit http://newsroom.gehealthcare.com/http://newsroom.gehealthcare.com

PRESS CONTACTS

Holly Langdon
GE Healthcare
1-414-721-3353
1-414-429-6998(mobile)
holly.langdon@ge.com

Full story

PositiveID’s iglucose™ mobile health system for diabetes management gets FDA clearance

PositiveID’s iglucose™ mobile health system for diabetes management gets FDA clearance

The Opportunity

According to the American Diabetes Association, “Keeping a log of your blood glucose results is vital. When you bring this record to your health care provider, you have a good picture of your body’s response to your diabetes care plan.” The problem is, for a variety of reasons, most people don’t keep journals of their blood glucose readings.

The Breakthrough

iglucose provides a breakthrough in diabetes management by automatically and wirelessly communicating blood glucose readings and creating logbooks and trend reports without the need for a mobile phone or manual entry. At the user’s consent, the data stored in the iglucose diabetes management portal can be shared automatically with family members, caregivers and healthcare professionals via text message, email or fax.

U.S Food and Drug Administration Clears PositiveID’s

iglucose System for Diabetes Management

iglucose is a First-of-its-Kind Wireless Communication System for Diabetes Management

PositiveID to Begin Commercialization Efforts in First Quarter 2012

DELRAY BEACH, Fla., Nov. 16, 2011 (GLOBE NEWSWIRE) — PositiveID Corporation (“PositiveID” or “Company”) (OTCBB:PSID), a developer of medical technologies for diabetes management and clinical diagnostics, announced today it has received clearance from the U.S. Food and Drug Administration (“FDA”) for its iglucose™ mobile health system for diabetes management. iglucose uses mobile technology to revolutionize the way individuals with diabetes manage their condition. By seamlessly communicating glucose readings from data-capable glucometers to the iglucose diabetes management portal, this important data can be shared with family members, caregivers and healthcare professionals. This makes it possible to improve care in a cost-effective manner and help loved ones manage their diabetes.

William J. Caragol, Chief Executive Officer of PositiveID stated, “iglucose is a safe, flexible, convenient, cost-effective and straightforward solution that we believe will revolutionize the way people with diabetes manage their condition. iglucose represents an opportunity to help decrease costs to our healthcare system by helping to improve disease management and patient compliance. This FDA clearance is an important validation of our product offering for PositiveID and we will work diligently to make iglucose available to everyone affected by diabetes in the near future.”

PositiveID believes that marketplace adoption for iglucose will be led by healthcare insurers and home-healthcare providers. The business model in this market will begin with initial roll-outs, followed by an evaluation period, and leading to broad scale adoption within the patient base. Over the coming months, PositiveID expects to launch initial roll-outs with several partners that it believes can lead to large orders of iglucose. PositiveID already has the wireless infrastructure in place through partnerships with AT&T in the U.S. and Rogers Communications in Canada, and will look to add additional wireless partners.

For years the American Diabetes Association and U.S. Centers for Disease Control and Prevention (“CDC”) have recommended that individuals with diabetes self-monitor and take a record of their glucose readings to their healthcare professionals. An American Association of Diabetes Educators (“AADE”) positioning statement revealed that self-monitoring is the best way for people with diabetes, as well as healthcare professionals, to assess the ongoing efficacy of all aspects of the diabetes management regimen, including medication and patient behavior. The problem is that most people do not keep consistent and accurate logbooks.

iglucose eliminates the burden of keeping manual logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition. iglucose uses mobile technology to seamlessly communicate blood glucose readings from an individual’s data-capable glucometer to the iglucose diabetes management portal, where, with the user’s consent, glucose readings can be shared automatically with family members, caregivers and healthcare professionals via text message, email or fax. iglucose does not require the use of a cell phone or a wireless plan.

The iglucose system collects and transmits stored data from a variety of FDA cleared blood glucose meters such as the LifeScan® OneTouch®, marketed by Johnson & Johnson, and Nipro Diagnostic™ True™ monitoring systems to a secure database via wireless cellular technology. A wireless data plan is not required. The Company is continually adding to this list of supported glucose meters.

PositiveID surveyed healthcare professionals at the AADE annual conference regarding the Company’s iglucose mobile health communication system to facilitate diabetes management and survey results showed 83 percent of diabetes educators believe using iglucose would improve patient outcomes; 82 percent of diabetes educators believe using iglucose would improve patient consults; and 76 percent of diabetes educators would recommend iglucose to their patients.

More than 25 million children and adults in the U.S. have diabetes, or over 8 percent of the population, according to the 2011 National Diabetes Fact Sheet. The CDC predicts that nearly 30 percent of children born after the year 2000 will develop diabetes. Worldwide, the number of adults with diabetes has doubled over the last three decades to nearly 350 million and increased nearly three-fold in the U.S., according to a study published in the British journal Lancet. The lifetime risk of developing diabetes for those born in the year 2000 is 35 percent. The total cost of diagnosed diabetes in the U.S. is estimated at $200 billion.

For more information on iglucose, please visit www.iglucose.com.

About PositiveID Corporation

PositiveID Corporation, based in Delray Beach, Florida, is a technology development company with two divisions: HealthID and MicroFluidic Systems. HealthID develops unique medical devices, focused primarily on diabetes management, and MicroFluidic Systems develops molecular diagnostic systems, focused primarily on bio-threat detection products. For more information on PositiveID, please visit www.PositiveIDCorp.com.

The PositiveID Corporation logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=7717

Statements about PositiveID’s future expectations, including the likelihood that iglucose makes it possible to improve care in a cost-effective manner and help loved ones manage their diabetes; the likelihood that iglucose is a safe, flexible, convenient, cost-effective and straightforward solution for people with diabetes to revolutionize the way they manage their condition; the likelihood that iglucose represents an opportunity to help decrease costs to our healthcare system by helping to improve disease management and patient compliance; the likelihood that this FDA clearance is an important validation of the Company’s product offering and the Company will work diligently to successfully make iglucose available to everyone affected by diabetes in the near future; the likelihood that the marketplace adoption for iglucose will be led by healthcare insurers and home-healthcare providers; the likelihood that the business model in this market will begin with initial roll-outs, followed by an evaluation period, and leading to broad scale adoption within the patient base; the likelihood that over the coming months, the Company will launch initial roll-outs with several partners that can lead to large orders of iglucose; the likelihood that PositiveID has the wireless infrastructure in place through partnerships with AT&T in the U.S. and Rogers Communications in Canada and will look to add additional wireless partners; the likelihood that iglucose eliminates the burden of keeping manual logbooks and empowers individuals with diabetes to be more engaged in the self-management of their condition; the likelihood that the Company is continually adding to this list of supported glucose meters; the likelihood that diabetes educators believe using iglucose would improve patient outcomes; the likelihood that diabetes educators believe using iglucose would improve patient consults; the likelihood that diabetes educators would recommend iglucose to their patients; the likelihood that nearly 30 percent of children born after the year 2000 will develop diabetes.; the likelihood that the lifetime risk of developing diabetes for those born in the year 2000 is 35 percent; the likelihood that the total cost of diagnosed diabetes in the U.S. is $200 billion; and all other statements in this press release other than historical facts are “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Litigation Reform Act of 1995. Such forward-looking statements involve risks and uncertainties and are subject to change at any time, and PositiveID’s actual results could differ materially from expected results. These risks and uncertainties include PositiveID’s ability to successfully commercialize iglucose and receive insurance reimbursement; as well as certain other risks. Additional information about these and other factors that could affect the Company’s business is set forth in the Company’s various filings with the Securities and Exchange Commission, including those set forth in the Company’s 10-K filed on March 25, 2011, and 10-Qs filed on May 13, 2011, August 15, 2011, and November 14, 2011, under the caption “Risk Factors.” The Company undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.

CONTACT: Allison Tomek

Full story

EndoCDx to Detect Adenocarcinoma Adenocarcinoma at an Earlier Stage

EndoCDx to Detect  Adenocarcinoma Adenocarcinoma at an Earlier Stage

NATIONAL HARBOR, MD, Oct 31, 2011 (MARKETWIRE via COMTEX) –

An important advance in the prevention of esophageal adenocarcinoma, the most rapidly growing cancer in the US, is being released for routine clinical use at the Annual Scientific Meeting of the American College of Gastroenterology taking place in National Harbor, M.D., being held from October 28 – November 2. Known as EndoCDx, this new method of testing the esophagus has been shown to dramatically increase the detection of still-harmless but precancerous cells, thus potentially saving many lives from this highly lethal disease. Esophageal adenocarcinoma, which is caused by the reflux of excess stomach acid into the esophagus, can theoretically be prevented if patients with heartburn receive an upper endoscopy to check for precancerous cells which can then be removed before the cancer is allowed to develop. While over 8 million Americans with heartburn see a gastroenterologist each year for this routine test, many of them with precancerous cells are currently being missed during their endoscopy. This is because the tissue sampling method used during an upper endoscopy relies on using a tiny forceps to test a large area of the esophagus and thus often fails to detect abnormal tissue that may be present. The newly released EndoCDx test solves this problem by utilizing a specially designed biopsy brush to test a much larger area of the esophagus than can be sampled by a forceps. This large partially disaggregated tissue sample is then subjected to a powerful three-dimensional computer assisted laboratory search for any precancerous cells. While CDx testing adds less than a minute to the standard upper endoscopy procedure it has been shown in large recently published clinical trials to increase the detection of both Barrett’s esophagus and esophageal dysplasia, the precancerous precursors of esophageal cancer, by over 40%, making it potentially one of the most recent significant advances in the prevention of any GI cancer. “Precancer of the esophagus is often invisible during endoscopy and gastroenterologists have long known that about 30% of patients with an abnormality are not being detected because the small biopsy forceps used to sample the esophagus did not happen to land on the abnormal area,” said Seth Gross, MD, Director of Advanced Endoscopy at Norwalk Hospital in Connecticut. He continued, “The over 40% increased pickup of disease provided by EndoCDx is a major advance in our goal of making esophageal cancer as preventable as colon cancer. We are therefore now adopting this technique to supplement all routine esophageal biopsies performed at our large regional esophagoscopy center.” Chronic exposure to stomach acids in patients with gastroesophageal reflux disease, or GERD, can damage the lining of the esophagus, leading to a condition called Barrett’s esophagus. In patients with Barrett’s esophagus, the normal cells lining the esophagus are replaced with tissue that is similar to the lining of the intestine.(1) It is believed that these cells (intestinal metaplasia) form as the body is trying to repair damage to the esophageal lining as a result of prolonged acid exposure.(2) Patients with intestinal metaplasia are at an increased risk for developing esophageal cancer. Each year, every one in 200 patients diagnosed with Barrett’s esophagus develops esophageal cancer. For advanced esophageal cancers, the current treatment options are limited, and odds of survival remain low.(3) About Barrett’s Esophagus Barrett’s esophagus is a precancerous condition affecting the lining of the esophagus. Barrett’s esophagus develops when the protective cells of the esophagus become damaged due to chronic stomach acid exposure. Patients with gastroesophageal reflux disease are at an increased risk for developing Barrett’s esophagus. Barrett’s esophagus itself does not cause symptoms. The acid reflux that causes Barrett’s esophagus often leads to symptoms of heartburn. However, many patients with this condition do not have symptoms. About Dysplasia Dysplasia occurs as a series of cell changes as Barrett’s esophagus progresses to Barrett’s-associated cancer. Dysplasia is considered a precancerous condition and should be monitored very closely to ensure the cells do not become cancerous. Dysplastic cells are very similar to cancer cells but have not yet acquired the ability to invade into tissue or metastasize. Patients with dysplasia are monitored very closely by their physician to ensure there is no further disease progression. About Esophageal Cancer Esophageal cancer is the fastest growing cancer in the United States(2). Esophageal cancer results when abnormal cells metastasize and penetrate the esophageal tissue. Esophageal cancer is usually not curable and once diagnosed just 16% of patients live for five or more years(1). Advanced screening and monitoring of patients with Barrett’s esophagus may lead to early detection and improved survival. About CDx Diagnostics CDx Diagnostics ( www.cdxdiagnostics.com ) is the world’s leader in the prevention of cancer of the aerodigestive tract including the oral cavity, pharynx, larynx and esophagus, through early detection of their pre-cancerous precursors. Clinicians use CDx patented brush biopsy instruments to non-invasively collect a wide area, disaggregated tissue specimen of the entire thickness of the suspect epithelium. This unique tissue specimen is then subjected to specialized, computer-assisted laboratory analysis. For further information please call (201) 843-5600. (1) Medical Position Statement on the Management of Barrett’s Esophagus,” published by the American Gastroenterological Association (AGA) Institute. Gastroenterology, March 2011. (2) What is Barrett’s Esophagus? Johns Hopkins University. http://pathology2.jhu.edu/beweb/Definition.cfm (3) Medical Position Statement on the Management of Barrett’s Esophagus,” published by the American Gastroenterological Association (AGA) Institute. The medical position statement was published in Gastroenterology, the official journal of the AGA Institute. For further information contact: Laura Yoshida Lazar Partners Ltd. 212-867-1762 lyoshida@lazarpartners.com SOURCE: CDx Diagnostics

Full story

CNAP (Continuous Noninvasive Arterial Pressure) technology in the United States

CNAP (Continuous Noninvasive Arterial Pressure) technology in the United States

Draeger Patient Monitors First to Offer Continuous Noninvasive Arterial

Pressure (CNAP) technology in the United States

October 31, 2011

Telford, PA – Draeger announces that it has embedded continuous noninvasive blood pressure measurement technology into its patient monitoring systems. This technology from CNSystems, which has successfully supported patients in Europe for more than four years, is now available in the United States. Draeger is the first and only vendor to offer CNAP technology, which can help hospitals increase patient safety and reduce costs.

The Infinity CNAP (Continuous Noninvasive Arterial Pressure) SmartPod provides a simple, accurate method for continuously measuring systolic, diastolic and mean blood pressure. CNAP technology provides the beat-to-beat vigilance of blood pressure changes equivalent to an invasive arterial line, while avoiding risks of complications and infections associated with the insertion of A-lines. The system is extremely easy to apply and use, and requires minimal training.

“Two of the biggest trends that continue in healthcare today are technologies that provide continuous data and are noninvasive to the patient,” says Product Manager David Blackmun. “With the Infinity CNAP SmartPod, Draeger provides hospitals with both of these attributes, which together can help improve patient safety and outcomes, while also saving costs.”

Seamless Monitoring of Blood Pressure

Raj Rane, Senior Clinical Engineer at Draeger, explains the clinical benefits of the technology: “CNAP fills the void in situations where NBP is not continuous and fast enough to detect critical blood pressure changes, and an A-line is too invasive, complicated, and expensive. In the past, the physician either had to place an invasive arterial catheter or rely completely on an oscillometric measurement, which only provides a value intermittently. CNAP measures the blood pressure painlessly, noninvasively and continuously in real time – thus detecting changes immediately. CNAP can also be used prior to insertion of the A-line, thus providing seamless blood pressure monitoring in the ICU or OR.”

The system works by integrating a light-emitting diode and detector into a double-finger sensor cuff. As the sensor detects changes in blood volume based on the amount of light transmitted through the finger, the cuff pressure closely follows the instantaneous pulsatile blood pressure changes in the finger arteries. Blood pressure can then be calculated beat-to-beat, after calibration with the built-in standard oscillometric measurement (NBP) of the monitor – and a high resolution, real-time arterial pressure waveform and systolic, diastolic and mean pressure value are displayed on the monitor.
The reliability and accuracy of the CNAP measurement during operations have been confirmed in clinical trials by renowned universities on more than 650 patients.

Draeger developed the CNAP pod to bring this innovative technology to its installed base of Infinity Omega and Omega-S solutions, as well as Delta, Delta XL and Kappa patient monitors.

For more information on Draeger and CNSystems, please visit www.draeger.com and www.cnsystems.at.

Draeger. Technology for Life®

Draeger is a leading international company in the fields of medical and safety technology. Draeger products protect, support and save lives. Founded in 1889, in 2010 Draeger generated revenues of around EUR 2.18 billion. The Draeger Group is currently present in more than 190 countries and has about 11,000 employees worldwide. Please visit www.draeger.com for more information.

CNSystems

Headquartered in Graz, Austria, CNSystems is technology leader in the development of noninvasive medical devices designed for real-time evaluation of all medical conditions characterized by rapid and short-term changes in hemodynamics. With CNAP®, the company succeeded in revolutionizing the method of non-invasive continuous blood pressure monitoring in anesthesiology and perioperative care.

Media Contacts:
Marion Varec: 215-660-2186
Pam Selker Rak: 412-221-4550

Full story

Third Eye Retroscope To Find More Adenomas During Colonoscopy

Third Eye Retroscope To Find More Adenomas During Colonoscopy

SUNNYVALE, CA, Oct 31, 2011 (MARKETWIRE via COMTEX) — Avantis Medical Systems, Inc., a technology leader in developing novel catheter-mounted digital imaging devices, today announced that results of a new analysis of its latest clinical data will be presented during the American College of Gastroenterology (ACG) 2011 Annual Scientific Meeting in Washington, D.C. The new abstract reports the results of subset analysis of a randomized, controlled trial to determine whether some patients might gain more benefit than others from colonoscopy that includes the use of the Third Eye(R) Retroscope(R), a retrograde-viewing camera. Avantis Medical Systems is exhibiting in booth #919 throughout the conference.

The report, titled “A Retrograde-Viewing Device Improves Adenoma Detection Rate in Colonoscopies for Surveillance and Diagnostic Workup,” was accepted by the ACG for oral presentation during the College’s plenary session on endoscopy on November 2, 2011, and for publication in a supplement to the October issue of the American Journal of Gastroenterology.(i) The abstract was additionally selected as the winner of the 2011 ACG International Award, which recognizes the best abstract submitted in any category by authors who are not based in the United States or Canada.

After looking at a number of other variables such as age, gender, quality of the bowel preparation and time spent examining the colon, they determined that the only variable that showed significant influence on the advantage provided by the Third Eye Retroscope was the indication for the procedure, i.e., the reason why the patient was having the colonoscopy. For patients who were undergoing colonoscopy for “surveillance” after previous removal of adenomas, the additional adenoma detection rate for Third Eye colonoscopy compared to standard colonoscopy was 35.7%. For patients having a “diagnostic” colonoscopy to look for a reason for symptoms such as anemia, weight loss, changes in bowel habits or rectal bleeding, the additional adenoma detection rate with Third Eye colonoscopy was 55.4%. The pooled results for these two “high risk” groups showed a 40.7% additional detection rate with Third Eye colonoscopy.

“The substantial and statistically significant improvement in adenoma detection rates provided by Third Eye colonoscopy for these groups points to a strong recommendation to use this device on all surveillance and diagnostic colonoscopy patients,” said Avantis Medical Systems’ Chief Medical Officer, Jack Higgins, MD.

The Principal Investigator for the trial was Peter D. Siersema, MD, PhD, who is the Director of the Department of Gastroenterology and Hepatology at University Medical Center Utrecht, in The Netherlands. According to Dr. Siersema, “As concerns about medical costs increase, there is growing interest in finding ways to target new technologies to specific groups of patients who are likely to experience the greatest benefit. While we didn’t demonstrate a significant advantage in screening patients, the evidence for effectiveness in non-screening patients is even more compelling than we had previously realized.”

The subset analysis was performed on results from the Third Eye Retroscope Randomized Clinical Evaluation (TERRACE), a randomized, controlled trial that provided the first head-to-head comparison between standard colonoscopy and Third Eye colonoscopy. Working at four sites in Europe and five in the U.S., the investigators performed two complete colonoscopy exams on each subject — one with and one without the Third Eye Retroscope. In an article published earlier this year in the journal, Gastrointestinal Endoscopy, they had reported the overall results of the study, which showed that with Third Eye colonoscopy they detected 23.2% additional pre-cancerous adenomas that had been missed with standard colonoscopy.(ii)

Although colonoscopy is the gold standard for preventing colon cancer by finding and removing pre-cancerous adenomas and other polyps, clinical literature documents that up to 21-24% of adenomas of all sizes can be missed.(iii, iv, v) In one study, 12% of large, advanced adenomas (at least 10 mm in size) were missed during colonoscopy, and two-thirds of the missed adenomas were hidden behind folds.(vi)

About the American College of Gastroenterology Founded in 1932, the American College of Gastroenterology (ACG) is an organization with an international membership of more than 12,000 individuals from 80 countries. The College is committed to serving the clinically-oriented digestive disease specialist through its emphasis on scholarly practice, teaching and research. The mission of the College is to serve the evolving needs of physicians in the delivery of high-quality, scientifically-sound, humanistic, ethical and cost-effective health care to gastroenterology patients. www.acg.gi.org

About the Third Eye Retroscope and Avantis Medical Systems, Inc.

Avantis Medical Systems, Inc. markets the Third Eye Retroscope, an FDA-cleared, disposable, catheter-based camera indicated for use with a standard colonoscope to provide an additional view of the colon for diagnostic purposes. It is inserted through the instrument channel of a standard colonoscope to provide the physician with a retrograde (backward) view of the lining of the colon. This retrograde view can reveal lesions that are hidden behind folds where they can’t be seen with the colonoscope’s forward view alone. The Third Eye has been shown in clinical studies to help physicians find up to 23-25% more pre-cancerous adenomas than a standard colonoscope alone.(ii, vii)

The Third Eye is the only technology that consistently enhances adenoma detection when used in conjunction with a colonoscope. Although colonoscopy is the gold standard for preventing colon cancer by finding and removing adenomas, clinical literature documents that up to 21-24% of adenomas of all sizes(iii, iv, v) and 12% of adenomas over 10 mm in size(vi) can be missed. The retrograde view provided by the Third Eye can reveal lesions that are hidden behind folds where they cannot be seen with the colonoscope’s forward view alone.

In October 2010, the Centers for Medicare & Medicaid Services (CMS) established a new outpatient pass-through C-code (C1749) for the Third Eye Retroscope, positioning the device for expedited adoption by healthcare providers, who can now submit claims for reimbursement for use of this clinically significant product.

Avantis Medical is focused on delivering cost-effective solutions for improved detection and prevention of cancers of the gastrointestinal tract. The company has an extensive portfolio of patents covering innovative devices based on the convergent technologies of micro-chips, enhanced video processing and catheter-based delivery systems. For more information, visit www.AvantisMedical.com or www.ThirdEyeRetroscope.com .

(i) Siersema P, Rastogi A, Leufkens A, et al. A Retrograde-Viewing Device Improves Adenoma Detection Rate in Colonoscopies for Surveillance and Diagnostic Workup. Am J Gastroenterol 2011; 106: S537-8. (Online at http://download.abstractcentral.com/ACG2011/proofs/67.html ) (ii) Leufkens AM, DeMarco DC, Siersema PD, et al. Effect of a Retrograde-Viewing Device on Adenoma Detection Rate during Colonoscopy: The “TERRACE” Study. Gastrointest Endosc 2011;73:480-90. (iii) Rex DK, Cutler CS, Mark DG, et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997;112:24-8. (iv) Van Rijn JC, Reitsma JB, Dekker E, et al. Polyp Miss Rate Determined by Tandem Colonoscopy: A Systemic Review. Am J Gastroenterol 2006;101:343-50. (v) Heresbach D, Barrioz T, Ponchon T, et al. Miss rate for colorectal neoplastic polyps: a prospective multicenter study of back-to-back video colonoscopies. Endoscopy 2008;40:284-90. (vi) Pickhardt PJ, Nugent PA, Schindler WR, et al. Location of adenomas missed by optical colonoscopy. Ann Intern Med 2004;141:352-9. (vii) DeMarco DC, Odstrcil E, Lara LF, et al. Impact of Experience with a Retrograde-Viewing Device on Adenoma Detection Rates and Withdrawal Times during Colonoscopy: The Third Eye Retroscope Study Group. Gastrointest Endosc 2010;71:542-50.

        
        Avantis Medical Systems, Inc.
        Grant Choe
        (408) 636-7237
        gchoe@avantismedical.com

Full story

GE 7T MRI to collaborate on Research into Brain Disorders ,University of Iowa

GE 7T MRI to collaborate on Research into Brain Disorders ,University of Iowa

“Our 7.0T MRI research system has the abilities to provide increased image resolution and sensitivity to help accelerate translational research. This collaboration is an excellent representation of how academic-industrial partnerships can help define new directions with the goal of facilitating more immediate health improvements and better outcomes.”

Full story

Copyright © 2017 Medical Technology & Gadgets Blog MedicalBuy.net. All rights reserved.
Proudly powered by WordPress. Developed by Deluxe Themes